Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $22.42 USD
Change Today -0.168 / -0.74%
Volume 4.6K
As of 10:00 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

sagent pharmaceuticals inc (SGNT) Key Developments

Sagent Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Full Year 2015

Sagent Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s net revenue was $82.6 million, an increase of $11.8 million, or 17%, compared to $70.9 million in the first quarter of 2014. The increase was driven primarily by the $7.4 million from the addition of Omega on October 1, 2014. Net loss of $1.9 million or diluted loss per share of $0.06, inclusive of $3.1 million ($0.10 per share) of costs related to management transition, acquisition-related costs and the inventory step up on Omega, net of tax. Adjusted EBITDA was $9.0 million, a decline of $0.5 million, or 6% compared to $9.6 million in the first quarter of 2014. Loss from operations was $189,000 compared to income from operations of $6,632,000 a year ago. Loss before income taxes was $1,575,000 compared to income before income taxes of $6,333,000 a year ago. EBITDA was $1,803,000 compared to $8,358,000 a year ago. For the year 2015, the company expected net revenue to be in the range of $325 to $375 million. The company anticipates adjusted EBITDA in the range of $20 to $50 million. The company expected EBITDA to be in the range of $11 million to $39 million. Expected net income to be in the range of $3 million loss to $13 million earnings. Adjusted gross profit will be in the range of 27% to 31%.

Sagent Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 05, 2015

Sagent Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 9:00 AM, US Eastern Standard Time on May 05, 2015

Sagent Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 05, 2015

Sagent Pharmaceuticals, Inc., Q1 2015 Earnings Call, May 05, 2015

Sagent Pharmaceuticals, Inc. Appoints Michael Logerfo as President

Sagent Pharmaceuticals, Inc. announced that its current EVP and Chief Legal Officer Michael Logerfo has been appointed President, effective April 15, 2015. In his new role as President, Mr. Logerfo will lead the company's Executive Management Committee, will continue to have primary responsibility over the company's strategic business development and legal functions, and will report to the Chairman of the Board. Mr. Logerfo has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Sagent since March 2012.

Shlomo Yanai Joins Sagent Pharmaceuticals, Inc.'s Board of Directors

Sagent Pharmaceuticals, Inc. announced that Shlomo Yanai has been appointed to its Board of Directors effective April 15, 2015. Mr. Yanai served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 until 2012.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGNT:US $22.42 USD -0.168

SGNT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $14.74 USD +0.07
Pernix Therapeutics Holdings Inc $6.45 USD -0.06
Pfizer Ltd/India 2,225 INR +9.70
SciClone Pharmaceuticals Inc $9.29 USD -0.01
Sucampo Pharmaceuticals Inc $16.13 USD +0.20
View Industry Companies
 

Industry Analysis

SGNT

Industry Average

Valuation SGNT Industry Range
Price/Earnings 22.4x
Price/Sales 2.4x
Price/Book 2.7x
Price/Cash Flow 22.1x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAGENT PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.